Success Metrics

Clinical Success Rate
85.7%

Based on 6 completed trials

Completion Rate
86%(6/7)
Active Trials
1(8%)
Results Posted
67%(4 trials)
Terminated
1(8%)

Phase Distribution

Ph phase_2
2
15%
Ph not_applicable
3
23%
Ph phase_1
2
15%
Ph phase_4
4
31%

Phase Distribution

2

Early Stage

2

Mid Stage

4

Late Stage

Phase Distribution11 total trials
Phase 1Safety & dosage
2(18.2%)
Phase 2Efficacy & side effects
2(18.2%)
Phase 4Post-market surveillance
4(36.4%)
N/ANon-phased studies
3(27.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

60.0%

6 of 10 finished

Non-Completion Rate

40.0%

4 ended early

Currently Active

1

trials recruiting

Total Trials

13

all time

Status Distribution
Active(3)
Completed(6)
Terminated(4)

Detailed Status

Completed6
Withdrawn3
Not yet recruiting1
Recruiting1
Terminated1
Enrolling by invitation1

Development Timeline

Analytics

Development Status

Total Trials
13
Active
1
Success Rate
85.7%
Most Advanced
Phase 4

Trials by Phase

Phase 12 (18.2%)
Phase 22 (18.2%)
Phase 44 (36.4%)
N/A3 (27.3%)

Trials by Status

completed646%
not_yet_recruiting18%
recruiting18%
terminated18%
withdrawn323%
enrolling_by_invitation18%

Recent Activity

Clinical Trials (13)

Drug Details

Intervention Type
PROCEDURE
Total Trials
13